Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

FDA approves Pfenex's osteoporosis therapy

Published 10/07/2019, 06:10 AM
Updated 10/07/2019, 06:16 AM
FDA approves Pfenex's osteoporosis therapy

FDA approves Pfenex's osteoporosis therapy

(Reuters) - The U.S. Food and Drug Administration on Monday approved a bone-building drug from Pfenex Inc to treat osteoporosis in certain patients at high risk for fractures, giving the company its first commercial product.

The company said it is seeking the FDA's authorization to designate the drug, PF708, as therapeutically equivalent to Eli Lilly (NYSE:LLY) and Co's injectable drug Forteo.

This would permit PF708 to be automatically substituted for Forteo, which lost its market exclusivity in many U.S. states in August.

Pfenex hopes to market PF708 as a cheaper option for Forteo, which brought in global revenue of $1.58 billion last year.

Pfenex said it was conducting a comparative study between PF708 and Forteo and expects to submit a final report to the FDA as early as the second half of October.

"We currently expect our commercial partner Alvogen to launch PF708 upon an FDA decision on the therapeutic equivalence rating," Pfenex Chief Executive Officer Eef Schimmelpennink said in a statement.

Analysts at William Blair expect PF708 to bring in sales of $96.1 million at its peak in 2021.

The company will receive a $2.5 million milestone payment from privately owned Alvogen for gaining U.S. approval.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.